Andrew Allen, Gritstone bio CEO (via website)
September 27, 2023 04:01 PM EDTUpdated 04:49 PM
R&D

Grit­stone inks up to $433M con­tract with BAR­DA for 10,000-per­son Covid-19 vac­cine tri­al

Kyle LaHucik

Senior Reporter

Grit­stone bio will get up to $433 mil­lion from the US gov­ern­ment to run a Phase IIb tri­al ear­ly next year test­ing its self-am­pli­fy­ing mR­NA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times